Myology research highlights
RSS feedThe SMYD3 methyltransferase promotes myogenesis by activating the myogenin regulatory network
The coordinated expression of myogenic regulatory factors, including MyoD and myogenin, orchestrates the steps of skeletal muscle development, from myoblast proliferation and cell-cycle exit, to myoblast fusion and myotubes maturation. Yet, it remains unclear how key transcription factors and epigenetic enzymes cooperate to guide myogenic differentiation. Proteins of the SMYD (SET and MYND domain-containing) methyltransferase … [Read more]
Targeted PMP22 TATA-box editing by CRISPR/Cas9 reduces demyelinating neuropathy of CMT1A in mice
Charcot-Marie-Tooth 1A (CMT1A) is the most common inherited neuropathy without a known therapy, which is caused by a 1.4 Mb duplication on human chromosome 17, which includes the gene encoding the peripheral myelin protein of 22 kDa (PMP22). Overexpressed PMP22 protein from its gene duplication is thought to cause demyelination and subsequently axonal degeneration in … [Read more]
Ankle bracing practices in ambulatory, corticosteroid-naive boys with DMD
Loss of ambulation in Duchenne muscular dystrophy presages scoliosis, respiratory failure, and death. Strategies to maintain ankle range of motion are employed, but little evidence exists to support these approaches and limited information is available concerning current practice. In this study the researchers assessed baseline bracing data from 187 boys participating in a multicenter, international … [Read more]
Next-generation sequencing approach to hyperCKemia: a 2-year cohort study
Next-generation sequencing (NGS) was applied in molecularly undiagnosed asymptomatic or paucisymptomatic hyperCKemia to investigate whether this technique might allow detection of the genetic basis of the condition. Sixty-six patients with undiagnosed asymptomatic or paucisymptomatic hyperCKemia, referred to tertiary neuromuscular centers over an approximately 2-year period, were analyzed using a customized, targeted sequencing panel able to … [Read more]
Low-intensity running and high-intensity swimming exercises differentially improve energy metabolism in mice with mild spinal muscular atrophy
Spinal Muscular Atrophy (SMA), an autosomal recessive neurodegenerative disease characterized by the loss of spinal-cord motor-neurons, is caused by mutations on Survival-of-Motor Neuron (SMN)-1 gene. The expression of SMN2, a SMN1 gene copy, partially compensates for SMN1 disruption due to exon-7 excision in 90% of transcripts subsequently explaining the strong clinical heterogeneity. Several alterations in … [Read more]
LGMD type R26: the involvement of a Popeye domain protein is confirmed
Limb Girdle Muscular Dystrophies (or LGMD) constitute a very heterogeneous group of neuromuscular diseases both clinically and genetically. Their nomenclature underwent a major revision in 2018 to better take into account their genotypic diversity. LGMDs have in common an impairment of the musculature proximal to the pelvic and scapular girdles and evolve in a very … [Read more]
A phase 3 multicenter, prospective, open-label efficacy and safety study of IgIV in patients with Myasthenia gravis exacerbations
Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular transmission. Exacerbations may involve increasing bulbar weakness and/or sudden respiratory failure, both of which can be critically disabling. Management of MG exacerbations includes plasma exchange and intravenous immunoglobulin (IVIG); they are equally effective, but patients experience fewer side effects with IVIG. The objective of this study … [Read more]
Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3, a prospective observational study
Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease caused by loss of the SMN1 gene. Based on randomized clinical trials in children with SMA type 1 and 2, Nusinersen has been approved as the first treatment for all types of SMA, including adults with SMA type 3. The authors evaluated the … [Read more]
Temporary reduction of membrane CD4 with the antioxidant MnTBAP is sufficient to prevent immune responses induced by gene transfer
Unexpectedly, the synthetic antioxidant MnTBAP was found to cause a rapid and reversible downregulation of CD4 on T cells in vitro and in vivo. This effect resulted from the internalization of membrane CD4 T cell molecules into clathrin-coated pits and involved disruption of the CD4/p56Lck complex. The CD4 deprivation induced by MnTBAP had functional consequences on CD4-dependent infectious processes … [Read more]
Risdiplam, on course for marketing authorisation in proximal spinal muscular atrophy
An application for marketing authorisation for risdisplam (RO7034067 ou RG7916), in the treatment of SMN1-related proximal spinal muscular atrophy (SMA) was submitted to the FDA (US Food and Drug Administration), by Roche and PTC Therapeutics, who are developing the product. Risdiplam is a small drug molecule administered orally that corrects SMN2 maturation to produce the … [Read more]